In TCGA skin cutaneous melanoma (SKCM) patient cohort dataset, where around half of the patients gained BRAF mutations, we investigated whether PRC2 deficiency affects clinical outcomes in patients. This evidence concerns the gene BRAF and cutaneous melanoma.